ARL17A

Summary

ARL17A (ARF like GTPase 17A, HGNC:24096) is a protein-coding gene on chromosome 17q21.31, encoding Putative ADP-ribosylation factor-like protein 17A (Q8IVW1). Putative small GTP-binding protein cycling between an inactive GDP-bound and an active GTP-bound form.

Predicted to enable GTP binding activity. Predicted to be involved in intracellular protein transport and vesicle-mediated transport. Predicted to be located in Golgi apparatus. Predicted to be active in cytoplasm and plasma membrane.

Source: NCBI Gene 51326 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 185 total — 4 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_001113738

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24096
Approved symbol	ARL17A
Name	ARF like GTPase 17A
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000185829
Ensembl biotype	protein_coding
Entrez	51326

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 19 protein_coding, 7 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000329240, ENST00000336125, ENST00000445552, ENST00000570550, ENST00000573185, ENST00000622488, ENST00000628873, ENST00000706245, ENST00000706246, ENST00000706247, ENST00000706248, ENST00000706249, ENST00000706250, ENST00000706251, ENST00000706252, ENST00000706253, ENST00000706254, ENST00000706255, ENST00000706256, ENST00000706257, ENST00000706258, ENST00000706259, ENST00000706260, ENST00000706261, ENST00000706302, ENST00000706303, ENST00000706304

RefSeq mRNA: 7 — MANE Select: NM_001113738 NM_001113738, NM_001288811, NM_001288812, NM_001288813, NM_001330244, NM_001411134, NM_016632

CCDS: CCDS45717, CCDS45718, CCDS74086, CCDS74087, CCDS82146, CCDS92351

Canonical transcript exons

ENST00000336125 — 4 exons

Exon	Start	End
ENSE00001706295	46552756	46557630
ENSE00002370780	46576175	46576339
ENSE00003806456	46570759	46570869
ENSE00003995309	46579601	46579691

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 91.03.

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	91.03	gold quality
bone marrow cell	CL:0002092	88.55	gold quality
colonic epithelium	UBERON:0000397	88.14	gold quality
sural nerve	UBERON:0015488	86.18	gold quality
tonsil	UBERON:0002372	85.63	gold quality
cortical plate	UBERON:0005343	85.55	gold quality
cerebellar cortex	UBERON:0002129	85.14	gold quality
cerebellar hemisphere	UBERON:0002245	85.14	gold quality
cerebellum	UBERON:0002037	85.11	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.91	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.80	gold quality
skeletal muscle tissue	UBERON:0001134	84.58	gold quality
adrenal tissue	UBERON:0018303	84.48	gold quality
bone marrow	UBERON:0002371	84.13	gold quality
right coronary artery	UBERON:0001625	83.45	gold quality
monocyte	CL:0000576	83.35	gold quality
ganglionic eminence	UBERON:0004023	83.20	gold quality
ventricular zone	UBERON:0003053	83.18	gold quality
muscle tissue	UBERON:0002385	83.14	gold quality
endometrium	UBERON:0001295	82.78	gold quality
prostate gland	UBERON:0002367	82.76	gold quality
leukocyte	CL:0000738	82.61	gold quality
left ovary	UBERON:0002119	82.61	gold quality
pituitary gland	UBERON:0000007	82.53	gold quality
ovary	UBERON:0000992	82.38	gold quality
body of uterus	UBERON:0009853	82.32	gold quality
popliteal artery	UBERON:0002250	82.30	gold quality
ectocervix	UBERON:0012249	82.30	gold quality
tibial artery	UBERON:0007610	82.29	gold quality
blood	UBERON:0000178	82.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.48

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

29 targeting ARL17A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-5100	99.11	67.52	1098
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-1288-5P	98.85	67.01	734
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-1265	98.36	66.46	598
HSA-MIR-6847-5P	97.93	66.74	1808
HSA-MIR-4433B-3P	97.22	63.62	663
HSA-MIR-4445-5P	97.21	66.16	832
HSA-MIR-6762-5P	96.55	64.62	972
HSA-MIR-6845-5P	96.55	64.65	969
HSA-MIR-4280	96.44	67.69	473
HSA-MIR-3135A	96.41	65.30	494
HSA-MIR-601	95.98	67.59	421

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arf2a	ENSDARG00000014763
mus_musculus	Arf2	ENSMUSG00000062421
rattus_norvegicus	Arf1	ENSRNOG00000004807
drosophila_melanogaster	Arf1	FBGN0010348
caenorhabditis_elegans		WBGENE00000182

Paralogs (30): ARF5 (ENSG00000004059), SAR1A (ENSG00000079332), ARFRP1 (ENSG00000101246), TRIM23 (ENSG00000113595), ARL6 (ENSG00000113966), ARL1 (ENSG00000120805), ARL4A (ENSG00000122644), ARL8B (ENSG00000134108), ARF3 (ENSG00000134287), ARL3 (ENSG00000138175), ARL5C (ENSG00000141748), ARF1 (ENSG00000143761), ARL8A (ENSG00000143862), ARL11 (ENSG00000152213), SAR1B (ENSG00000152700), ARL5A (ENSG00000162980), ARF6 (ENSG00000165527), ARL5B (ENSG00000165997), ARF4 (ENSG00000168374), ARL13B (ENSG00000169379), ARL13A (ENSG00000174225), ARL10 (ENSG00000175414), ARL4D (ENSG00000175906), ARL14 (ENSG00000179674), ARL15 (ENSG00000185305), ARL4C (ENSG00000188042), ARL9 (ENSG00000196503), ARL2 (ENSG00000213465), ARL16 (ENSG00000214087), ARL17B (ENSG00000228696)

Protein

Protein identifiers

Putative ADP-ribosylation factor-like protein 17A — Q8IVW1 (reviewed: Q8IVW1)

All UniProt accessions (14): A0A087WVX3, A0A087WY76, A0A994J582, A0A994J5A8, A0A994J5H2, A0A994J5U5, A0A994J7P5, A0A994J7P8, A8K0M5, Q8IVW1, I3L1A0, I3L1V5, I3L2E4, I3L3L1

UniProt curated annotations — full annotation on UniProt →

Function. Putative small GTP-binding protein cycling between an inactive GDP-bound and an active GTP-bound form.

Similarity. Belongs to the small GTPase superfamily. Arf family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IVW1-1	1	yes
Q8IVW1-2	2
Q8IVW1-4	4

RefSeq proteins (8): NP_001107210, NP_001275740, NP_001275741, NP_001275742, NP_001317169, NP_001317173, NP_001398063, NP_057716 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006689	Small_GTPase_ARF/SAR	Family
IPR024156	Small_GTPase_ARF	Family
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR031687	ARL17_C	Domain

Pfam: PF00025, PF15840

UniProt features (8 total): splice variant 2, initiator methionine 1, chain 1, region of interest 1, lipid moiety-binding region 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IVW1-F1	53.86	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 81 (showing top): CCAWYNNGAAR_UNKNOWN, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, WALLACE_PROSTATE_CANCER_RACE_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, YGCGYRCGC_UNKNOWN, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, chr12q24, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN, HMGIY_Q6, TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C, DAVICIONI_MOLECULAR_ARMS_VS_ERMS_UP, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP, NFY_Q6_01, ZWANG_DOWN_BY_2ND_EGF_PULSE, PTEN_DN.V1_DN

GO Biological Process (3): intracellular protein transport (GO:0006886), vesicle-mediated transport (GO:0016192), protein transport (GO:0015031)

GO Molecular Function (3): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166)

GO Cellular Component (3): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
transport	2
protein transport	1
intracellular transport	1
cellular process	1
establishment of protein localization	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1961 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARL17A	KANSL1	Q7Z3B3	769
ARL17A	LRRC37A2	A6NM11	720
ARL17A	LRRC37A	A6NMS7	714
ARL17A	LRRC37A3	O60309	712
ARL17A	ARHGAP27	Q6ZUM4	558
ARL17A	PLEKHM1	Q9Y4G2	512
ARL17A	SPPL2C	Q8IUH8	479
ARL17A	ARL16	Q0P5N6	447
ARL17A	NXPE3	Q969Y0	445
ARL17A	SLC29A4	Q7RTT9	402
ARL17A	CRHR1	P34998	400
ARL17A	R3HDM2	Q9Y2K5	400
ARL17A	MAPT	P10636	398
ARL17A	RIPOR1	Q6ZS17	375
ARL17A	ARL9	Q6T311	374

IntAct

16 interactions, top by confidence:

A	B	Type	Score
TSPAN3	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
ARL17A	GGT7	psi-mi:“MI:0915”(physical association)	0.400
P		psi-mi:“MI:0914”(association)	0.350
KCNA2	TMEM129	psi-mi:“MI:0914”(association)	0.350
PCDH10	TMEM223	psi-mi:“MI:0914”(association)	0.350
TTMP	TMEM223	psi-mi:“MI:0914”(association)	0.350
PIPSL	C1orf226	psi-mi:“MI:0914”(association)	0.350
FTL	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
TMEM74	KLRG2	psi-mi:“MI:0914”(association)	0.350
RNF149	CCDC85C	psi-mi:“MI:0914”(association)	0.350
CX3CL1	FAM171A2	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
MICB	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
LHFPL2	SRC	psi-mi:“MI:0914”(association)	0.350

BioGRID (22): ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-RNA), ARL17A (Affinity Capture-MS), GGT7 (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS), ARL17A (Affinity Capture-MS)

ESM2 similar proteins: A0A3T0QHT2, A0A5Q0QMX6, A1A4F0, C0H3V9, F4IXT6, N4WW42, O05023, O59008, O81514, P03850, P08834, P0CF86, P0CF87, P0CV25, P19680, P26947, P37143, P39351, P44218, P49997, P55457, P84705, P84714, P86265, P92512, P92516, P92520, P92522, P92523, P92555, P93281, P93290, Q04616, Q04977, Q06517, Q13278, Q13670, Q14T82, Q2UPB6, Q2XXR3

Diamond homologs: O00909, O23778, O48649, O48920, P0CM16, P0CM17, P0DH91, P11076, P18085, P19146, P22274, P25160, P26990, P26991, P34212, P34727, P36397, P36406, P36407, P36579, P38116, P40616, P40940, P40945, P40946, P40994, P49076, P49702, P49703, P51643, P51644, P51645, P51646, P51821, P51822, P51823, P51824, P56559, P61204, P61205

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

185 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	131
Likely benign	27
Benign	14

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
150568	GRCh38/hg38 17q21.31(chr17:45579327-46661960)x1	Pathogenic
4083492	GRCh37/hg19 17q21.31(chr17:43861911-44630815)x1	Pathogenic
57050	GRCh38/hg38 17q21.31(chr17:45629520-46661960)x1	Pathogenic
815938	GRCh37/hg19 17q21.31(chr17:43655356-44784639)x3	Pathogenic
3338434	GRCh37/hg19 17q21.31(chr17:44248221-44772028)x1	Likely pathogenic

SpliceAI

2271 predictions. Top by Δscore:

Variant	Effect	Δscore
17:46520284:G:GG	donor_gain	1.0000
17:46520288:G:GG	donor_gain	1.0000
17:46523156:G:GG	donor_gain	1.0000
17:46523882:GTT:G	donor_gain	1.0000
17:46540878:AACT:A	donor_gain	1.0000
17:46540879:ACT:A	donor_gain	1.0000
17:46540880:CT:C	donor_gain	1.0000
17:46540881:TGTAA:T	donor_loss	1.0000
17:46540882:G:C	donor_loss	1.0000
17:46540882:G:GG	donor_gain	1.0000
17:46540883:T:TC	donor_loss	1.0000
17:46546371:GTC:G	donor_gain	1.0000
17:46546374:G:GG	donor_gain	1.0000
17:46546408:T:G	donor_gain	1.0000
17:46546408:T:TG	donor_gain	1.0000
17:46553393:A:AG	acceptor_gain	1.0000
17:46553398:A:C	acceptor_loss	1.0000
17:46553399:GAT:G	acceptor_gain	1.0000
17:46553399:GATAT:G	acceptor_gain	1.0000
17:46555280:TCTA:T	acceptor_loss	1.0000
17:46555282:TAG:T	acceptor_loss	1.0000
17:46555283:A:AG	acceptor_gain	1.0000
17:46555283:AG:A	acceptor_gain	1.0000
17:46555283:AGGAT:A	acceptor_gain	1.0000
17:46555284:G:GG	acceptor_gain	1.0000
17:46555284:GG:G	acceptor_gain	1.0000
17:46555284:GGA:G	acceptor_gain	1.0000
17:46555284:GGAT:G	acceptor_gain	1.0000
17:46555284:GGATG:G	acceptor_gain	1.0000
17:46555417:GACCC:G	donor_gain	1.0000

AlphaMissense

1166 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:46570865:G:C	F51L	0.987
17:46570865:G:T	F51L	0.987
17:46570867:A:G	F51L	0.987
17:46570822:A:G	W66R	0.951
17:46570822:A:T	W66R	0.951
17:46576251:A:C	S24R	0.943
17:46576251:A:T	S24R	0.943
17:46576253:T:G	S24R	0.943
17:46576234:T:A	K30I	0.942
17:46570829:G:C	F63L	0.930
17:46570829:G:T	F63L	0.930
17:46570831:A:G	F63L	0.930
17:46570775:A:C	F81L	0.928
17:46570775:A:T	F81L	0.928
17:46570777:A:G	F81L	0.928
17:46570820:C:A	W66C	0.917
17:46570820:C:G	W66C	0.917
17:46576264:A:G	I20T	0.909
17:46570817:A:C	D67E	0.908
17:46570817:A:T	D67E	0.908
17:46570866:A:G	F51S	0.907
17:46576233:T:A	K30N	0.907
17:46576233:T:G	K30N	0.907
17:46570824:A:T	V65D	0.902
17:46570786:A:G	W78R	0.900
17:46570786:A:T	W78R	0.900
17:46576213:A:G	L37S	0.900
17:46576231:G:A	T31I	0.900
17:46570818:T:C	D67G	0.894
17:46570818:T:G	D67A	0.893

dbSNP variants (sampled 300 via entrez): RS1000032920 (17:46553066 A>G), RS1000040171 (17:46533354 T>A,G), RS1000302562 (17:46511301 A>G), RS1000413102 (17:46516336 T>C), RS1000542732 (17:46551406 T>C), RS1001153620 (17:46520269 A>C,G), RS1001393235 (17:46549605 A>G), RS1001700977 (17:46504948 A>C,G), RS1001719948 (17:46550862 AATG>A), RS1001771499 (17:46533199 C>T), RS1002083840 (17:46517535 C>T), RS1002151698 (17:46506163 T>G), RS1002434760 (17:46516873 A>G), RS1002545847 (17:46502328 G>A), RS1003179453 (17:46530646 A>G)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:189800, MIM:610443

GenCC curated gene-disease

Mondo (2): preeclampsia (MONDO:0005081), Koolen-de Vries syndrome (MONDO:0012496)

Orphanet (2): Preeclampsia (Orphanet:275555), Koolen-De Vries syndrome (Orphanet:96169)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST004621_193	Red cell distribution width	3.000000e-32
GCST006268_228	Reaction time	2.000000e-16
GCST006661_283	Male-pattern baldness	4.000000e-27
GCST007267_238	Systolic blood pressure	2.000000e-12
GCST007269_306	Pulse pressure	9.000000e-16
GCST007592_2	Handedness (Left-handed vs. non-left-handed)	1.000000e-09
GCST007594_2	Handedness (Right-handed vs. non-right-handed)	2.000000e-08
GCST008839_128	Height	4.000000e-08
GCST010135_31	Oily fish consumption	5.000000e-09
GCST010140_21	Pork consumption	5.000000e-09
GCST010703_91	Brain morphology (MOSTest)	2.000000e-65
GCST011207_4	Left ventricular mass	2.000000e-06
GCST011208_6	Left ventricular mass to end-diastolic volume ratio	4.000000e-07
GCST011214_7	Left ventricle wall thickness	2.000000e-11
GCST90002391_94	Mean corpuscular hemoglobin concentration	3.000000e-10
GCST90010427_24	Left–right brain asymmetry	8.000000e-15

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0009188	Red cell distribution width
EFO:0008393	reaction time measurement
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0009902	handedness
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0009289	left ventricular mass
EFO:0010556	Left ventricular mass to end-diastolic volume ratio
EFO:0008205	left ventricular structural measurement
EFO:0004528	mean corpuscular hemoglobin concentration

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases expression	1
chlorophyllin	increases expression, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
bisphenol S	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases expression, decreases reaction	1
Dexamethasone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases expression	1
Vanadates	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
Copper Sulfate	increases expression	1
Lactic Acid	increases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial